Elixir Pharmaceuticals is a company focused on age-related diseases such as diabetes and obesity. Elixir released new data on research that ultimately could lead to a treatment for type 2 diabetes.

The research explains the role of ghrelin, a hormone secreted by the stomach. Ghrelin controls appetite by increasing levels before meals and decreasing levels after meals. A lack of sleep produces ghrelin, which stimulates appetite and creates less leptin which, amongst its many other effects, suppresses appetite. Research scientists have developed an anti-obesity vaccine, which is directed against the hormone ghrelin. The vaccine uses the immune system antibodies to prevent ghrelin from reaching the central nervous system, thus producing a desired reduction in weight gain.

The research conducted by Elixir, as well as the obesity vaccination, shows compelling evidence that ghrelin plays a pivotal role in metabolic regulation. Scientists have shown pharmacologic inhibition of the ghrelin receptor results in a reduction in fasting glucose levels, reduction in insulin resistance, and weight loss. This could lead to victorious battle for science in the war on obesity.